Growth Metrics

Adaptive Biotechnologies (ADPT) Net Income towards Common Stockholders: 2018-2025

Historic Net Income towards Common Stockholders for Adaptive Biotechnologies (ADPT) over the last 8 years, with Sep 2025 value amounting to $9.5 million.

  • Adaptive Biotechnologies' Net Income towards Common Stockholders rose 129.74% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year increase of 59.25%. This contributed to the annual value of -$159.6 million for FY2024, which is 29.16% up from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Net Income towards Common Stockholders is $9.5 million, which was up 137.30% from -$25.6 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Net Income towards Common Stockholders high stood at $9.5 million for Q3 2025, and its period low was -$69.5 million during Q4 2023.
  • In the last 3 years, Adaptive Biotechnologies' Net Income towards Common Stockholders had a median value of -$46.2 million in 2024 and averaged -$39.2 million.
  • In the last 5 years, Adaptive Biotechnologies' Net Income towards Common Stockholders plummeted by 72.94% in 2023 and then soared by 129.74% in 2025.
  • Quarterly analysis of 5 years shows Adaptive Biotechnologies' Net Income towards Common Stockholders stood at -$61.4 million in 2021, then skyrocketed by 34.53% to -$40.2 million in 2022, then crashed by 72.94% to -$69.5 million in 2023, then skyrocketed by 51.46% to -$33.7 million in 2024, then surged by 129.74% to $9.5 million in 2025.
  • Its last three reported values are $9.5 million in Q3 2025, -$25.6 million for Q2 2025, and -$29.8 million during Q1 2025.